Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series.

The purpose of the study was to analyse the generalisability and geographic transportability of survival estimates produced by commonly used prognostic factors. We compared the influence of tumour size, histologic grade, axillary nodal status, oestrogen and progesterone receptor contents, age at diagnosis and two prognostication schemes (the Nottingham Prognostic Index and St. Gallen criteria) in two nationwide cohorts of patients diagnosed with breast cancer in 1991-2, the FinProg (n=2923, Finland) and the SEER series (n=43,249, the United States (US)). Eight-year estimates of breast cancer-specific (84% versus 80%), relative (86% versus 83%), and overall (70% versus 69%) survival were slightly more favourable in the SEER than in the FinProg series, respectively. Despite differences in demographic variables and the frequency of use of adjuvant therapies and mammography screening between the series, the prognostic factors examined produced close to overlapping survival curves with similar shapes. The results suggest that quantitative survival estimates based on frequently used prognostic factors and prognostication schemes are generalisable and transportable between large, unselected cohorts of breast cancer patients.

[1]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[2]  M. Hakama,et al.  Process indicators from ten centres in the Finnish breast cancer screening programme from 1991 to 2000. , 2004, European journal of cancer.

[3]  A. Gafni,et al.  A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer , 1992, Annals of Internal Medicine.

[4]  M. Coleman,et al.  Breast carcinoma survival in Europe and the United States , 2004, Cancer.

[5]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[6]  D K Wagener,et al.  Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. , 2001, Journal of the National Cancer Institute.

[7]  Sten Thorstenson,et al.  Applying the Nottingham Prognostic Index to a Swedish breast cancer population , 2004, Breast Cancer Research and Treatment.

[8]  E. Feuer,et al.  Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. , 2002, Journal of the National Cancer Institute.

[9]  R. W. Scarff,et al.  Histological typing of breast tumors. , 1982, Tumori.

[10]  Katrina Armstrong,et al.  Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Dean,et al.  Screening mammography in Finland--1.5 million examinations with 97 percent specificity. Mammography Working Group, Radiological Society of Finland. , 1999, Acta oncologica.

[12]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[14]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[16]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[17]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[18]  V. Kataja,et al.  Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Kataja,et al.  Risk for distant recurrence of breast cancer detected by mammography screening or other methods. , 2004, JAMA.

[20]  Mikael Lundin,et al.  A web-based system for individualised survival estimation in breast cancer , 2003, BMJ : British Medical Journal.

[21]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Karen A Gelmon,et al.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Clegg,et al.  Adjuvant therapy for breast cancer: practice patterns of community physicians. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .